These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15886158)

  • 1. Overcoming economic barriers to the optimal use of vaccines.
    Lieu TA; McGuire TG; Hinman AR
    Health Aff (Millwood); 2005; 24(3):666-79. PubMed ID: 15886158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The problems and promise of vaccine markets in developing countries.
    Batson A
    Health Aff (Millwood); 2005; 24(3):690-3. PubMed ID: 15886160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Policy analysis: an essential research tool for the introduction of vaccines in developing countries.
    Mahoney R
    J Health Popul Nutr; 2004 Sep; 22(3):331-7. PubMed ID: 15609786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines as a global imperative--a business perspective.
    Stéphenne J
    Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What are today's orphaned vaccines?
    Wilde H
    Clin Infect Dis; 2001 Sep; 33(5):648-50. PubMed ID: 11486287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.
    Batson A; Meheus F; Brooke S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotavirus vaccines: targeting the developing world.
    Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
    J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines.
    Saxenian H; Cornejo S; Thorien K; Hecht R; Schwalbe N
    Health Aff (Millwood); 2011 Jun; 30(6):1122-33. PubMed ID: 21653966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introducing new vaccines into developing countries: obstacles, opportunities and complexities.
    Clemens J; Jodar L
    Nat Med; 2005 Apr; 11(4 Suppl):S12-5. PubMed ID: 15812482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The introduction of new vaccines into developing countries. IV: Global Access Strategies.
    Mahoney RT; Krattiger A; Clemens JD; Curtiss R
    Vaccine; 2007 May; 25(20):4003-11. PubMed ID: 17363119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financing vaccines: in search of solutions that work.
    Iglehart JK
    Health Aff (Millwood); 2005; 24(3):594-5. PubMed ID: 15886147
    [No Abstract]   [Full Text] [Related]  

  • 15. Strengthening the supply of routinely recommended vaccines in the United States: a perspective from the American Medical Association.
    Tan L;
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S121-4. PubMed ID: 16447133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of priority vaccines for disease-endemic countries: risk and benefit.
    Milstien J; Cash RA; Wecker J; Wikler D
    Health Aff (Millwood); 2005; 24(3):718-28. PubMed ID: 15886166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement.
    Andrus JK; Sherris J; Fitzsimmons JW; Kane MA; Aguado MT
    Vaccine; 2008 Aug; 26 Suppl 10():K87-92. PubMed ID: 18847561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Veterinary vaccines and their use in developing countries.
    Lubroth J; Rweyemamu MM; Viljoen G; Diallo A; Dungu B; Amanfu W
    Rev Sci Tech; 2007 Apr; 26(1):179-201. PubMed ID: 17633302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine advance-purchase agreements for low-income countries: practical issues.
    Berndt ER; Hurvitz JA
    Health Aff (Millwood); 2005; 24(3):653-65. PubMed ID: 15886157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.